Genetic polymorphisms in CYP2E1: Association with schizophrenia susceptibility and risperidone response in the chinese han population

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Huo, Ran ^a,b   Tang, Kefu ^a,b   Wei, Zhiyun ^a,b   Shen, Lu ^a,b   Xiong, Yuyu ^a,b   Wu, Xi ^a,b   Niu, Jiamin ^c   Han, Xia ^c   Tian, Zhengan ^d   Yang, Lun ^a,b   Feng, Guoyin ^a,b,e   He, Lin ^a,b,f   Qin, Shengying ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Shanghai Genomepilot Institutes   (China)

^c Laiwu Hospital   (China)

^d Shanghai International Travel Healthcare Center   (China)

^e SHANGHAI MENTAL HEALTH CENTER   (China)

^f FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2E1; RISPERIDONE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CHINESE; CONTROLLED STUDY; CYP2E1 GENE; DNA FLANKING REGION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE; GENE FREQUENCY; GENE FUNCTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PHARMACOGENETICS; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; ADOLESCENT; ASIAN; CASE CONTROL STUDY; CHINA; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; VARIABLE NUMBER OF TANDEM REPEAT;

5' FLANKING REGION; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHINA; CYTOCHROME P-450 CYP2E1; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; MINISATELLITE REPEATS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RISPERIDONE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84861006752     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034809     Document Type: Article

References (56)

1. Schultz SK, Andreasen NC, (1999) Schizophrenia. Lancet 353: 1425-1430.
2. Andreasen NC, Arndt S, Alliger R, Miller D, Flaum M, (1995) Symptoms of schizophrenia. Methods, meanings, and mechanisms. Arch Gen Psychiatry 52: 341-351.
3. O'Donovan MC, Craddock N, Norton N, Williams H, Peirce T, et al. (2008) Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet 40: 1053-1055.
4. Need AC, Ge D, Weale ME, Maia J, Feng S, et al. (2009) A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS Genet 5: e1000373.
5. Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, et al. (2009) Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 460: 753-757.
6. Stefansson H, Rujescu D, Cichon S, Pietilainen OP, Ingason A, et al. (2008) Large recurrent microdeletions associated with schizophrenia. Nature 455: 232-236.
7. Ortiz de Montellano PR, (2005) Cytochrome P450: structure, mechanism, and biochemistry. New York Kluwer Academic/Plenum Publishers. xx, 689 p. p.
8. Hanioka N, Tanaka-Kagawa T, Miyata Y, Matsushima E, Makino Y, et al. (2003) Functional characterization of three human cytochrome p450 2E1 variants with amino acid substitutions. Xenobiotica 33: 575-586.
9. Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP, et al. (1990) Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxicol 3: 566-573.
10. Guengerich FP, Kim DH, Iwasaki M, (1991) Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 4: 168-179.
11. Kharasch ED, Thummel KE, (1993) Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology 79: 795-807.
12. Lieber CS, (1997) Cytochrome P-4502E1: its physiological and pathological role. Physiol Rev 77: 517-544.
13. Bolt HM, Roos PH, Thier R, (2003) The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and environmental medicine. Int Arch Occup Environ Health 76: 174-185.
14. Hu Y, Hakkola J, Oscarson M, Ingelman-Sundberg M, (1999) Structural and functional characterization of the 5'-flanking region of the rat and human cytochrome P450 2E1 genes: identification of a polymorphic repeat in the human gene. Biochem Biophys Res Commun 263: 286-293.
15. Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, et al. (2003) Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 37: 924-930.
16. Dey A, Kumar SM, (2011) Cytochrome P450 2E1 and hyperglycemia-induced liver injury. Cell Biol Toxicol 27: 285-310.
17. Wang YD, Yang HY, Li L, Wang HY, Zhang CK, et al. (2010) Association between CYP2E1 genetic polymorphisms and lung cancer risk: A meta-analysis. European Journal of Cancer 46: 758-764.
18. Tang K, Li Y, Zhang Z, Gu Y, Xiong Y, et al. (2010) The PstI/RsaI and DraI polymorphisms of CYP2E1 and head and neck cancer risk: a meta-analysis based on 21 case-control studies. BMC Cancer 10: 575.
19. Ogony J, Matthews R, Anni H, Shannon K, Ercal N, (2008) The mechanism of elevated toxicity in HepG2 cells due to combined exposure to ethanol and ionizing radiation. J Appl Toxicol 28: 345-355.
20. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, et al. (2004) Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 9: 684-697, 643.
21. Iwahashi K, Nakamura K, Furukawa A, Okuyama E, Miyatake R, et al. (1997) No linkage of the cytochrome P-450IIE1 (CYP2E1) C1/C2 polymorphism to schizophrenia. Hum Exp Toxicol 16: 208-211.
22. Kane JM, (1996) Schizophrenia. N Engl J Med 334: 34-41.
23. Heck AH, Haffmans PM, de Groot IW, Hoencamp E, (2000) Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial. Schizophr Res 46: 97-105.
24. Csernansky JG, Schuchart EK, (2002) Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 16: 473-484.
25. Riedel M, Schwarz MJ, Strassnig M, Spellmann I, Muller-Arends A, et al. (2005) Risperidone plasma levels, clinical response and side-effects. Eur Arch Psychiatry Clin Neurosci 255: 261-268.
26. Xing Q, Gao R, Li H, Feng G, Xu M, et al. (2006) Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics 7: 987-993.
27. Lencz T, Robinson DG, Xu K, Ekholm J, Sevy S, et al. (2006) DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry 163: 529-531.
28. Reynolds GP, Yao Z, Zhang X, Sun J, Zhang Z, (2005) Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. Eur Neuropsychopharmacol 15: 143-151.
29. Wang L, Yu L, He G, Zhang J, Zhang AP, et al. (2007) Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients. Neurosci Lett 414: 1-4.
30. Lane HY, Chang YC, Chiu CC, Chen ML, Hsieh MH, et al. (2002) Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. Am J Psychiatry 159: 1593-1595.
31. Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, et al. (1993) Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 54: 257-268.
32. Fang J, Bourin M, Baker GB, (1999) Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol 359: 147-151.
33. van Beijsterveldt LE, Geerts RJ, Leysen JE, Megens AA, Van den Eynde HM, et al. (1994) Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology (Berl) 114: 53-62.
34. Wang L, Yu L, Zhang AP, Fang C, Du J, et al. (2007) Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia. J Psychopharmacol 21: 837-842.
35. Du J, Zhang A, Wang L, Xuan J, Yu L, et al. (2010) Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients. J Psychopharmacol 24: 1115-1120.
36. Tang K, Li X, Xing Q, Li W, Feng G, et al. (2010) Genetic polymorphism analysis of cytochrome P4502E1 (CYP2E1) in Chinese Han populations from four different geographic areas of Mainland China. Genomics 95: 224-229.
37. American Psychiatric Association, (1994) Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Press, Washington, DC, USA.
38. Overall JE, Gorham DR, (1962) The Brief Psychiatric Rating Scale. Psychol. Rep.10, 799-812.
39. Olesen OV, Linnet K, (1997) Simplified high-performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in serum from patients comedicated with other psychotropic drugs. J Chromatogr B Biomed Sci Appl 698: 209-216.
40. Shi YY, He L, (2005) SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 15: 97-98.
41. Barrett JC, Fry B, Maller J, Daly MJ, (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265.
42. Faul F, Erdfelder E, Lang AG, Buchner A, (2007) G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39: 175-191.
43. Wigginton JE, Cutler DJ, Abecasis GR, (2005) A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet 76: 887-893.
44. Hansson T, Tindberg N, Ingelman-Sundberg M, Kohler C, (1990) Regional distribution of ethanol-inducible cytochrome P450 IIE1 in the rat central nervous system. Neuroscience 34: 451-463.
45. Montoliu C, Sancho-Tello M, Azorin I, Burgal M, Valles S, et al. (1995) Ethanol increases cytochrome P4502E1 and induces oxidative stress in astrocytes. J Neurochem 65: 2561-2570.
46. Schulz JB, Lindenau J, Seyfried J, Dichgans J, (2000) Glutathione, oxidative stress and neurodegeneration. Eur J Biochem 267: 4904-4911.
47. Cadet JL, Lohr JB, (1987) Free radicals and the developmental pathobiology of schizophrenic burnout. Integr Psychiatry 51: 40-48.
48. Smythies JR, (1997) Oxidative reactions and schizophrenia: a review-discussion. Schizophr Res 24: 357-364.
49. Lee SA, Haiman CA, Burtt NP, Pooler LC, Cheng I, et al. (2007) A comprehensive analysis of common genetic variation in prolactin (PRL) and PRL receptor (PRLR) genes in relation to plasma prolactin levels and breast cancer risk: the multiethnic cohort. BMC Med Genet 8: 72.
50. Gregg C, Shikar V, Larsen P, Mak G, Chojnacki A, et al. (2007) White matter plasticity and enhanced remyelination in the maternal CNS. J Neurosci 27: 1812-1823.
51. Xing QH, Wu SN, Lin ZG, Li HF, Yang JD, et al. (2003) Association analysis of polymorphisms in the upstream region of the human dopamine D4 receptor gene in schizophrenia. Schizophr Res 65: 9-14.
52. Tao R, Li C, Zheng Y, Qin W, Zhang J, et al. (2007) Positive association between SIAT8B and schizophrenia in the Chinese Han population. Schizophr Res 90: 108-114.
53. Carter CJ, (2006) Schizophrenia susceptibility genes converge on interlinked pathways related to glutamatergic transmission and long-term potentiation, oxidative stress and oligodendrocyte viability. Schizophr Res 86: 1-14.
54. Mauri MC, Laini V, Boscati L, Rudelli R, Salvi V, et al. (2001) Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels. Eur Psychiatry 16: 57-63.
55. Spina E, Avenoso A, Facciola G, Salemi M, Scordo MG, et al. (2001) Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology (Berl) 153: 238-243.
56. Lee BH, Kim YK, (2006) The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients. Prog Neuropsychopharmacol Biol Psychiatry 30: 658-662.